Previous close | 1.5000 |
Open | 1.7000 |
Bid | 1.5000 |
Ask | 1.7500 |
Strike | 25.00 |
Expiry date | 2024-06-21 |
Day's range | 1.6500 - 1.7000 |
Contract range | N/A |
Volume | |
Open interest | 717 |
PASADENA, Calif., May 20, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar lavage
Comprehensive Analysis of ARWR's Fiscal 2024 Q2 Earnings Against Market Forecasts
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript May 9, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and […]